Sanara MedTech Inc. is a medical technology company that develops and commercializes soft tissue repair and bone fusion products for the surgical market. Its primary products include CellerateRX Surgical, a hydrolyzed collagen for wound management, and BIASURGE, a sterile surgical solution for wound irrigation. The company also offers bone fusion solutions such as BiFORM, an osteoconductive implant, and ALLOCYTE Plus, a human allograft cellular bone matrix. Additional products in its portfolio include TEXAGEN Amniotic Membrane Allograft, ACTIGEN Verified Inductive Bone Matrix, and FORTIFY TRG Tissue Repair Graft. Sanara MedTech markets and sells these products to surgeons at hospitals and ambulatory surgical centers, primarily in the United States. The company utilizes an in-house research and development team, Rochal Technologies, to advance its product pipeline. In 2023, the company signed an exclusive license agreement with Tufts University for collagen peptide technology, leading to the formation of the subsidiary Sanara Collagen Peptides, LLC, though this agreement is currently in the process of termination. The company previously operated a value-based wound care program called Tissue Health Plus (THP), which was discontinued in September 2025 to refocus exclusively on surgical products.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage sanaramedtech.com
Sector Healthcare IR page ir.sanaramedtech.com
Tags
soft tissue repair, bone fusion, wound care, surgical solutions, collagen peptides, allografts, osteoconductive implants, CellerateRX Surgical, BIASURGE, BiFORM, ALLOCYTE Plus, TEXAGEN, ACTIGEN, FORTIFY TRG, Rochal Technologies, Sanara Collagen Peptides LLC, Tissue Health Plus
Press page —

Metrics

Valuation  
Market cap $ 322.688M
Market cap (USD) $ 322.688M
P/E -702.80
PEG —
P/BV 42.10
P/S 2.88
P/OCF 43.47
P/FCF 44.26
Dividend yield —
Turnover / mcap —
Returns  
ROE -165.7%
ROI -72.4%
ROIC 10.6%
Profit margin -36.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 609.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 42
Quality score -29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 103.118M 86.672M 64.99M 45.843M 24.144M 15.587M — 5.838M 6.305M 5.508M 3.372M 2.633M 1.726M 1.174M 2.21M 288.021K 290.183K — —
Net profit -37.563M -9.665M -4.303M -7.937M -7.994M -4.356M — -600.574K 331.309K -415.747K -1.34M -2.278M -4.148M -1.845M -12.741M -2.303M -1.773M — —
Free cash flow 2.161M -229.632K -3.511M -5.702M -4.986M -4.579M — 268.66K -183.757K 406.216K -1.208M -1.695M -1.852M — — — — 20.08K 5.356K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006
Share price 23.35 33.2 41.1 45.5 29.56 49.89 8.3 — — — — — — — — — — — —
Price performance 12m -0.3 -0.19 -0.1 0.54 -0.41 5.01 — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 0.00 79,787 6.81M — — 12M
↳ YoY growth +8,429.9%
Borrowings, current (USD) — — — 0.00 — — — 580,357 — —
Borrowings, non-current (USD) — — — — — — — 9.11M 30.7M 46M
Lease liabilities (USD) — — 0.00 598,917 481,384 425,443 819,224 2.1M 1.6M 2.22M
Cash and deposits (USD) 833,480 463,189 731,849 6.61M 455,366 18.7M 8.96M 5.15M 15.9M 16.6M
Intangible assets (USD) 140,336 117,291 52,266 1.47M 3.1M 4.73M 31.5M 44.9M 41M 18.6M
Right-of-use assets (USD) — — 0.00 585,251 467,653 412,770 806,402 2M 1.45M 2.08M
Net debt (borrowings + leases - cash) (USD) — — — -6.01M — — — 6.64M 16.4M 31.6M
Cash flow detail
Operating cash flow (USD) 409,245 -139,862 277,142 -2.17M -4.03M -4.81M -5.55M -3.25M -23,784 6.79M
Purchases of property, plant and equipment (USD) -3,029 -43,895 -8,482 -182,825 -544,374 -171,867 -147,015 -265,246 -205,848 -4.63M
Purchases of intangible assets (USD) 0.00 -41,980 0.00 -1.52M -1.1M -578,586 -600,000 — -23,452 -23,452
Change in receivables (cash effect) (USD) 503,233 64,413 -609,233 -324,368 -961,462 -695,018 -2.25M -1.82M -4.51M -114,690
Change in inventories (cash effect) (USD) 91,226 420,423 -262,886 — -719,810 -1.15M -517,271 -1.55M 1.44M -1.78M
Change in payables (cash effect) (USD) 15,877 26,942 -171,283 -65,037 -66,253 166,903 -301,966 531,380 -424,318 813,999
Interest paid (cash effect) (USD) -49,559 -10,937 0.00 -43,985 0.00 -711 -206 -283,948 -1.58M -3.35M
Income taxes paid (cash effect) (USD) 0.00 0.00 0.00 0.00 0.00 — — — -40,586 -48,792
Share-based compensation (USD) — — — 0.00 1.4M 2.67M 2.7M 3.44M 4.44M 5.15M
Operating cash flow before change in receivables (USD) -93,988 -204,275 886,375 -1.84M -3.07M -4.12M -3.3M -1.42M 4.49M 6.9M
Free cash flow (OCF - PPE - intangibles) (USD) 406,216 -225,737 268,660 -3.87M -5.68M -5.56M -6.3M -3.51M -253,084 2.14M
Income detail
Research and development expense (USD) — — — — 40,190 558,704 3.37M 4.13M 5.7M 5.07M
↳ 5y CAGR +163.2%
Provision for credit losses (USD) 10,735 22,207 12,558 110,000 30,000 51,536 280,000 202,941 624,448 509,233
Credit cost ratio (credit losses / average receivables) (%) — — — — — 129.2% 8.1% — — —
Reported Mar 29, 2018 Mar 29, 2018 May 20, 2019 Mar 30, 2021 Mar 31, 2022 Mar 31, 2022 Mar 20, 2023 Mar 25, 2024 Mar 24, 2026 May 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Summary(1)

● Net revenue increased 8% to $28.4 million, compared to $26.3 million in the third quarter of 2025.

● Gross profit of $26.3 million, or 93% of net revenue, compared to gross profit of $24.5 million, or 93% of net revenue, in the third quarter of 2025.

● Operating income of $0.7 million, compared to operating income of $2.9 million in the third quarter of 2025. Third quarter operating income included approximately $3.0 million in legal and advisory services associated with corporate strategic initiatives and the pending merger with MiMedx Group, Inc. (“MIMEDX” and the proposed transaction, the “Merger”).

On October 6, 2026, Sanara MedTech Inc. (the “Company”) sold all of the assets of Tissue Health Plus, LLC, a wholly owned subsidiary of the Company (“THP”), including THP’s business software products and related intellectual property, to an unrelated third party for a purchase price of approximately $2,000,000 and received certain earnout rights.

Sanara MedTech Inc. — Other Events Bull 0 Bear 0 Routine

As previously announced, Sanara MedTech Inc., a Texas corporation (the “Company” or “Sanara”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MiMedx Group, Inc., a Florida corporation (“MiMedx”), and Mustang Merger Sub, Inc., a wholly-owned subsidiary of MiMedx (“Merger Subsidiary”), pursuant to which, among other things and subject to the terms and conditions of the Merger Agreement, Merger Subsidiary will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly-owned subsidiary of MiMedx.

On October 15, 2026, the Company and MiMedx each received a request for additional information and documentary materials (a “Second Request”) from the Federal Trade Commission (the “FTC”) in connection with the FTC’s review of the Merger. The effect of a Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), until 30 days after the parties have substantially complied with the Second Request, unless that period is extended voluntarily by the parties or terminated earlier by the FTC.

Prompts

Sanara MedTech Inc. (ticker SMTI), listed in United States.

Company History

Date Change Detail
May 16, 2019 Renamed WOUND MANAGEMENT TECHNOLOGIES, INC. → SANARA MEDTECH INC.
Aug 12, 2008 Renamed MB SOFTWARE CORP → WOUND MANAGEMENT TECHNOLOGIES, INC.

ETFs Holding Sanara MedTech Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 8,320 $ 272.563K Nov 16, 2026
DFSU 0.00% 439 $ 14.285K Nov 12, 2026
DFAS 0.00% 3,305 $ 107.545K Nov 12, 2026
DFAC 0.00% 509 $ 16.563K Nov 12, 2026